ARCT
ARCT clinical trials: Arcturus Therapeutics Holdings Inc.
Every trial on ClinicalTrials.gov where Arcturus Therapeutics Holdings Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 13
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ARCT on the catalyst calendar · ARCT registry changes
- Primary completion Jun 13, 2025ActualPhase 1/Phase 2NCT06602531Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsArcturus Therapeutics, Inc. · Influenza, HumanCompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT06747858Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisArcturus Therapeutics, Inc. · Cystic FibrosisRecruitingARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2024ActualPhase 3NCT06279871Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsArcturus Therapeutics, Inc. · COVID-19CompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 10, 2024ActualPhase 1NCT06125691Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in AdultsArcturus Therapeutics, Inc. · Influenza, HumanCompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2023ActualPhase 1/Phase 2NCT05037097A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy AdultsArcturus Therapeutics, Inc. · COVID-19CompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2024ActualPhase 2NCT05526066Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810Arcturus Therapeutics, Inc. · Ornithine Transcarbamylase DeficiencyTerminatedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2022ActualPhase 2NCT04668339A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsArcturus Therapeutics, Inc. · Covid19TerminatedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2026Sponsor estimatePhase 2NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDArcturus Therapeutics, Inc. · OTC DeficiencyRecruitingARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2021ActualPhase 2NCT04728347Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021Arcturus Therapeutics, Inc. · SARS-CoV-2TerminatedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2024ActualPhase 1NCT05712538Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.Arcturus Therapeutics, Inc. · Cystic FibrosisCompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2023ActualPhase 1NCT04442347Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase...Arcturus Therapeutics, Inc. · Ornithine Transcarbamylase DeficiencyCompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2020ActualPhase 1NCT04416126Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult SubjectsArcturus Therapeutics, Inc. · Ornithine Transcarbamylase DeficiencyCompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2021ActualPhase 1/Phase 2NCT04480957Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult SubjectsArcturus Therapeutics, Inc. · SARS-CoV-2CompletedARCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2028Sponsor estimatePhase 2NCT07390968Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsFred Hutchinson Cancer Center · Hematopoietic and Lymphatic System NeoplasmNot yet recruitingARCTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2023ActualPhase 2/Phase 3NCT05012943The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)Vinbiocare Biotechnology Joint Stock Company · COVID-19 VaccinesCompletedARCTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner